Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Trying to be a member of the NASH club.

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 23, 2021 5:56pm

75 Views

Post# 32860611

RE:RE:RE:Trying to be a member of the NASH club.

One last podcast.
https://surfingnash.com/s2-e14-nash-tag-session-4-summary-basic-science-and-promising-drugs-on-the-horizon/
It starts with KOLs contemplating Ph2 without biopsy which would pretty much negate everything I've said about a hole in the data if it was instigated today. But the thing that got me most excited was Tesamorelin got mentioned at 33:30. Blink and you'd miss it, it was little more than a name check, but since THTX didn't present in the promising drug session (or at all in the conference) it's great that at least one KOL acknowledged its existence. More of that would be nice.

qwerty22 wrote:

https://surfingnash.com/s2-e11-nash-tag-session-1-summary-major-drugs-in-development-and-why-trials-fail/

Discussion on some of this conference. First 10 mins COVID (maybe skip). Some interesting points after that on the placebo effect in NASH trials. Really interesting at 50mins when they start discussing non-progression of fibrosis (as approved to regression) as a potential endpoint given what was seen in the Egrifta trial.

palinc2000 wrote: 8:40 – 8:55 What Would NASH Trials without Biopsy Look Like? Presenter: Vlad Ratziu, MD Hpital Piti Sal

qwerty22 wrote: https://www.nash-tag.org/sponsors